Companies/US/BMY

BRISTOL-MYERS SQUIBB COMPANY

Income flow

Annual
BMY 10-K Income StatementPeriod 2025-12-31Source 10-K
Sales Revenue Gross$18BNet Product Sales$10BGrowth Brands$5BLegacy Brands$4BEliquis$3BOpdivo$2BOrencia$763MRevlimid$608MYervoy$597MPomalyst Imnovid$563MReblozyl$479MOther Growth Brands$396MAlliance And Other Revenues$296MBreyanzi$280MOpdualag$244MCamzyos$220MOtherrevenues$204MOther Legacy Brands$164MZeposia$119MSprycel$101MAlliance Revenues$92MAbecma$88MAbraxane$76MSotyktu$60MOpdivo Ovantig$49MKrazati$42MCobenfy$32MRevenue$48B-0% Y/YGross profit$34B-0% Y/YCost of revenue$14BOperating profit$9BOperating expenses$25BNet profit$7B+179% Y/YTax$2BR&D & other$18BSG&A$7B

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 10-K · USD
By activity
By activity$234.1B
  • Sales Revenue Gross$88.1B37.6%
  • Net Product Sales$46.8B20.0%
  • Growth Brands$26.4B11.3%
  • Legacy Brands$21.8B9.3%
  • Eliquis$14.4B6.2%
  • Opdivo$10.0B4.3%
  • Orencia$3.7B1.6%
  • Revlimid$3.0B1.3%
  • Yervoy$2.9B1.2%
  • Pomalyst Imnovid$2.7B1.2%
  • Reblozyl$2.3B1.0%
  • Other Growth Brands$1.9B0.8%
  • Alliance And Other Revenues$1.4B0.6%
  • Breyanzi$1.4B0.6%
  • Opdualag$1.2B0.5%
  • Camzyos$1.1B0.5%
  • Otherrevenues$992M0.4%
  • Other Legacy Brands$798M0.3%
  • Zeposia$577M0.3%
  • Sprycel$493M0.2%
  • Alliance Revenues$447M0.2%
  • Abecma$427M0.2%
  • Abraxane$368M0.2%
  • Sotyktu$291M0.1%
  • Opdivo Ovantig$238M0.1%
  • Krazati$205M0.1%
  • Cobenfy$155M0.1%
By geography
By geography$48.2B
  • United States$33.3B69.0%
  • Non-US$13.8B28.7%
  • Other Region$1.1B2.3%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).4.45%5y avgAverage dividend yield over the past five years — a smoother view than the latest print.3.85%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).2.51PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.55.3%Shares outTotal shares currently outstanding (issued and not retired).2.04BFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).2.04B
Upcoming dividend
Ex-dividend
2026-10-02
Next pay
2026-11-02
Last cash
0.63 · 2026-10-02
Stock splits
  1. 1000000:9517772001-08-07

Valuation

Trailing PE 14.9 (2025-12-31)PE trend

Fiscal PE4

PeriodEPSClosePE
2025-12-313.4651.6414.9
2023-12-313.8644.5511.5
2022-12-312.9560.3120.4
2021-12-313.1250.6916.3

PE = stored close ÷ as-filed diluted EPS (annual 10-K / 20-F). Not a vendor PE series.